Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals Reports Third Quarter 2026 Financial Results and Highlights Recent Period Progress

Alnylam reported Q3 2026 net product revenues of $1,292 million, up 52% year-over-year, led by AMVUTTRA at $1,130 million (+65%) on strong U.S. ATTR-CM demand. Total revenues rose 17% to $1,458 million; GAAP net income of $2.17 billion was inflated by a $1.9 billion non-cash tax valuation-allowance release, with non-GAAP diluted EPS of $16.26 up 410%. The company reiterated its FY2026 guidance of $4.7-$5.1 billion in net product revenues and expanded the TRITON-CM Phase 3 enrollment target to 2,250 patients, still targeting a nucresiran ATTR-CM launch by 2030. Positive Phase 1 data for brezosiran in Huntington's disease (60-64% mean CSF mHTT reduction at month 3) support a pivotal study in 2027, in collaboration with Regeneron.

•3d ago

Alnylam Announces Positive Initial Phase 1b Data for Brezosiran (ALN-HTT02) Demonstrating Deep and Durable Huntingtin Lowering in Huntington’s Disease

Alnylam reported positive initial Phase 1b data for brezosiran (ALN-HTT02), an investigational RNAi therapeutic for Huntington's disease, with mean CSF mutant huntingtin reductions of 60-64% at month 3 and up to 83% in individuals in the highest dose group evaluated. The data, presented at the EHDN Clinical Research Congress in Krakow, show an encouraging safety profile through up to 12 months of follow-up with no dose-dependent increases in CSF inflammatory markers, NfL, or brain ventricular volume, supporting potential twice-yearly dosing. Alnylam plans a placebo-controlled pivotal study in 2027 pending regulatory alignment; the program is being developed in collaboration with Regeneron Pharmaceuticals. Brezosiran will be featured at Alnylam's RNAi Roundtable on October 26, 2026.

•10d ago

Singapore is the first ASEAN country to provide government subsidy for eligible patients receiving vutrisiran for transthyretin amyloidosis

Singapore has become the first ASEAN nation to subsidize vutrisiran (AMVUTTRA) through the Medication Assistance Fund, offering up to 75% cost coverage for eligible patients with hATTR-PN or ATTR-CM. The reimbursement decision by the Agency for Care Effectiveness is supported by clinical data from the HELIOS-A and HELIOS-B Phase 3 trials, including a 28% reduction in all-cause mortality for cardiomyopathy patients. Alnylam's partner Medison Pharma will drive commercialization in the region, leveraging the new government support to expand patient access to the RNAi therapeutic.

•2mo ago

Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings

Alnylam presented new data at ESC Congress 2026 demonstrating that Vutrisiran provided consistent clinical benefits across all-cause mortality and recurrent cardiovascular events in ATTR-CM patients, regardless of baseline Tafamidis use. Additional post hoc analyses showed Vutrisiran treatment led to 25% less decline in intrinsic capacity and a 52% reduction in the risk of decline, while pooled data across four Phase 3 studies confirmed consistent treatment effects across sexes in 1,402 patients. Data from the KARDIA-3 Phase 2 study for Zilebesiran highlighted the potential for enhanced blood pressure control with biannual dosing, particularly in patients with high baseline systolic blood pressure.

•2mo ago

Alnylam to Present New Data Reinforcing Strength in RNAi-Powered TTR Silencing and Continued Progress in Hypertension at ESC Congress 2026

Alnylam announced it will present new clinical and real-world data for AMVUTTRA (vutrisiran) and zilebesiran at the ESC Congress 2026, reinforcing its leadership in ATTR and progress in hypertension. Presentations for AMVUTTRA include a Late-Breaking Science analysis from the HELIOS-B Phase 3 study evaluating patients on background stabilizer therapy, alongside real-world data on the multisystem burden of ATTR-CM. The hypertension program features a subgroup analysis from the KARDIA-3 Phase 2 study of zilebesiran combined with a diuretic; the asset is currently in Phase 3 CV outcomes trial ZENITH, co-developed with Roche.

•2mo ago

Alnylam Highlights Progress with Neuroscience Programs at AAIC 2026, Showcasing Potential of RNAi in Neurological Disease

Alnylam presented updated Phase 1 data for Mivelsiran in early-onset Alzheimer’s disease, showing robust biomarker reductions of up to 90% with no evidence of increased ARIA risk. The company initiated a global Phase 2 study for Down Syndrome-associated Alzheimer’s and completed enrollment in a Phase 2 study for Cerebral Amyloid Angiopathy. Additionally, Alnylam shared preclinical data and design for the tau-targeting ALN-5288, an asset being developed in collaboration with Regeneron.

•3mo ago

Komodo Expands Strategic Partnership With Alnylam to Scale AI-Powered Intelligence Platform

Alnylam expanded its strategic partnership with Komodo Health to deploy the Marmot AI analytics platform across its entire enterprise. The adoption of the platform is intended to replace fragmented reporting with real-time, verifiable healthcare intelligence, significantly reducing reporting cycles. Chief Commercial Officer Tolga Tanguler stated that the new capability will help scale operations and accelerate decision-making while maintaining focus on patients.

•4mo ago

GENESIS Pharma Expands Strategic Commercial Partnership with Alnylam Pharmaceuticals for RNAi Therapeutics to the Nordic Region

Alnylam Pharmaceuticals has expanded its longstanding commercial partnership with GENESIS Pharma to include four Nordic markets: Denmark, Finland, Norway, and Sweden. This expansion adds to the existing coverage of 13 Southeast European markets, bringing GENESIS Pharma’s total coverage to 24 countries in Europe for Alnylam’s RNAi therapeutics. The deal grants GENESIS Pharma rights to commercialize Alnylam’s portfolio for serious cardiomyopathy conditions and rare genetic diseases across the expanded territory.

•4mo ago

Alnylam and Inceptive Form Strategic AI Collaboration to Accelerate the Discovery of RNAi Therapeutics

Alnylam Pharmaceuticals has entered a strategic collaboration with Inceptive Nucleics to leverage AI foundation models for the discovery of RNAi therapeutics. The deal is valued at up to $2 billion, including a $30 million upfront payment comprising cash and equity in Inceptive, with additional payments tied to preclinical, regulatory, and commercial milestones. This partnership integrates Inceptive’s generative AI with Alnylam’s proprietary siRNA data and R&D engine, aiming to accelerate drug discovery timelines and support Alnylam’s 'Alnylam 2030' strategy.

•4mo ago

Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM

Alnylam announced it will present new analyses from the Phase 3 HELIOS-B study for vutrisiran in patients with ATTR-CM at the Heart Failure 2026 congress. The presentations highlight a consistent clinical profile and support the use of vutrisiran as a first-line treatment, including in patients with high disease burden or those on concomitant therapies. Additional analyses cover pharmacodynamic subgroups, pooled safety data regarding vitamin A, and the design of the long-term observational study DemonsTTRate.

•5mo ago

Alnylam Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Period Progress

Alnylam delivered a record quarter with $1.036 billion in global net product revenues, up 121% year-over-year, marking the first time quarterly product sales exceeded $1 billion. The performance was fueled by AMVUTTRA and ONPATTRO, which together generated $910 million in TTR revenues, prompting the company to reiterate its full-year 2026 revenue guidance of $4.9 billion to $5.3 billion. Additionally, the company established new collaborations with Viz.ai and the American Heart Association to improve ATTR-CM care, while advancing pipeline candidates including ALN-2232 for obesity into Phase 1 trials.

•6mo ago